Here is a list of Health Blogs ordered by Most Liked, posted by members. A Blog is a journal you may enter about your life, thoughts, interesting experiences, or lessons you've learned. Post an opinion, impart words of wisdom, or talk about something interesting in your day. Update your blog on a regular basis, or just whenever you have something to say. Creating a blog is a good way to share something of yourself with others. Reading blogs is a good way to learn more about others. Click here to post a blog.
Eat first, then exercise _or_ exercise first then eat...
I'm sure there are dozens of websites posting facts about which one is correct... one way or another. As for me, I prefer the order of exercising first, eating second then relaxing (and possibly taking a nap) third.
Years ago I had a girlfriend who professed her knowledge of healthy living.
Okay... do your thing!
No, I just had a big meal and I don't want to 'walk if off'
Maybe exercise improves your digestion. For me it causes indigestion.
Exercise after a meal steals the energy my body uses to digest food.
I'll get back to you in 30 minutes or less.
Yeah, and I do have an example... a pack of lions chase down their prey, devour it and hang out swatting flies with their tails. It has always been thus...
They don't have internet to tell them otherwise.
Thanks for reading my blog!
Honey... I'm home.
Years ago I had a girlfriend who professed her knowledge of healthy living.
Okay... do your thing!
No, I just had a big meal and I don't want to 'walk if off'
Maybe exercise improves your digestion. For me it causes indigestion.
Exercise after a meal steals the energy my body uses to digest food.
I'll get back to you in 30 minutes or less.
Yeah, and I do have an example... a pack of lions chase down their prey, devour it and hang out swatting flies with their tails. It has always been thus...
They don't have internet to tell them otherwise.
Thanks for reading my blog!
Honey... I'm home.
LIFE HAS CHANGED, new update
Noticed the new comments and wanted to reply by saying thank you so much for your concern.
I have finished all radiation and chemotherapy and just got back my MRI reports and everything is looking good, now I will be soon starting my immunotherapy for 1 year.
As far as I feel now, I feel good. When dealing with brain cancer you don't walk away without damage to the brain. I do not live a life of depression it is a life of frustration, your whole life has changed. I have problems with some communications but I seem to be able to perform good. I still have to be careful with being dizzy and don't do things to tire myself out. Overall all so far I believe things are going well
Once again thank you for your concern, prayers, strong energy you send me. Bless you
I have finished all radiation and chemotherapy and just got back my MRI reports and everything is looking good, now I will be soon starting my immunotherapy for 1 year.
As far as I feel now, I feel good. When dealing with brain cancer you don't walk away without damage to the brain. I do not live a life of depression it is a life of frustration, your whole life has changed. I have problems with some communications but I seem to be able to perform good. I still have to be careful with being dizzy and don't do things to tire myself out. Overall all so far I believe things are going well
Once again thank you for your concern, prayers, strong energy you send me. Bless you
In the news...
Every day, there's at least one Trump 'something' the media finds important to post about the president. There are way too many to remember all of them, but some highlights of the past few weeks:
Buying Greenland.
King of Israel.
Wanting to be allowed more than 2 terms.
Giving 'made up awards' to himself.
Having distanced himself from anything related to Jeffery Epstein for more than a decade, he told the media they should be looking at Clinton.
Ending the week with the best one I've heard all year...
Trump suggested we fire nuclear weapons at hurricanes to stop them hitting America.
I've tagged this blog under health because the man needs to see a mental health specialist.
Buying Greenland.
King of Israel.
Wanting to be allowed more than 2 terms.
Giving 'made up awards' to himself.
Having distanced himself from anything related to Jeffery Epstein for more than a decade, he told the media they should be looking at Clinton.
Ending the week with the best one I've heard all year...
Trump suggested we fire nuclear weapons at hurricanes to stop them hitting America.
I've tagged this blog under health because the man needs to see a mental health specialist.
I'm Mrs Scrooge
... and I like it.
All this Christmas circus, hypocrisy and consumerism.... makes me sick, lock my door and close the shutters.
.... and adding the nonsense called *waiting for the New Year.....
....... no, it's not me - crazy is the world.
When I feel like helping or giving presents, I don't wait for Christmas, or birthday, or whatever the numbers of the calendar.
The crowd festivities, never makes me happy.
All this Christmas circus, hypocrisy and consumerism.... makes me sick, lock my door and close the shutters.
.... and adding the nonsense called *waiting for the New Year.....
....... no, it's not me - crazy is the world.
When I feel like helping or giving presents, I don't wait for Christmas, or birthday, or whatever the numbers of the calendar.
The crowd festivities, never makes me happy.
Do You Pay Attention To Your Body? You Should.
It started about six years ago. I was having pains in my hips and my lower back and arms. My doctor would give me a prescription for pain. Well that was not helping so I asked what is causing this? It was hard to move, it hurt to bend or twist. I finally was told its probably inflammation. When I got home I spent the rest of the day searching google to find relief. I was taking prescriptions that were not helping,it had been about three years. I found that taking a spice from India, turmeric is very good for inflammation. I found that a tablespoon is a proper dose. You need to take black pepper with the turmeric for best results. I do not believe that I can put that much in my omelet. So I use a teaspoon instead. Then for my evening meal I use a teaspoon again and this has worked well for me. I have slacked off the turmeric and the pain is back in my right arm, so I bought two pounds of turmeric at Amazon. I am going to get rid of it again. I do not waste money on the pills and capsules that are being sold. Also I now look to google if something does not feel right before going to the doctor. It has been an expensive lesson to learn. I hope this will be helpful information for other people.
I Liked It Better When....
Father Time was an absentee parent.
I often hear about how we're destroying the planet and bringing about a mass extinction. What I'm not hearing about is the senseless slaughter of minutes, hours and days!
The killing of time is a real thing, people! Each and every day, thousands of seconds are obliterated. Hundreds of innocent minutes are thrown to the wayside without a 'second' thought.
Where is the outrage?
Hmmm, now that I think about it, I'm probably guilty of killing off a year or two.
I often hear about how we're destroying the planet and bringing about a mass extinction. What I'm not hearing about is the senseless slaughter of minutes, hours and days!
The killing of time is a real thing, people! Each and every day, thousands of seconds are obliterated. Hundreds of innocent minutes are thrown to the wayside without a 'second' thought.
Where is the outrage?
Hmmm, now that I think about it, I'm probably guilty of killing off a year or two.
in control
when nothing ever goes my way
heading to not so pleasant day
my gown is dirty
I am the bride
an awesome feeling
enjoying the ride
so good to know
thank you radio
heading to not so pleasant day
my gown is dirty
I am the bride
an awesome feeling
enjoying the ride
so good to know
thank you radio
"WAKE UP PEOPLE, WAKE UP... !!"
That's a quote.. it wasn't me doing the shouting.
I've been listening to a few videos by Doctor Vong and this guy talks about the reality of coronavirus. The death rate will increase. Hospitals are at capacity, medical staff are working without proper protective equipment and are falling to the virus. Doctors are dying.
He states percentages of risk factors for people who are obese, have hypertension, are diabetic and have respiratory disease. Those on ventilators have an average stay of 2 weeks. He gives details how the virus attacks the lungs and his explanations (with diagrams) are very clear and easy to understand.
Worth a listen.
I've been listening to a few videos by Doctor Vong and this guy talks about the reality of coronavirus. The death rate will increase. Hospitals are at capacity, medical staff are working without proper protective equipment and are falling to the virus. Doctors are dying.
He states percentages of risk factors for people who are obese, have hypertension, are diabetic and have respiratory disease. Those on ventilators have an average stay of 2 weeks. He gives details how the virus attacks the lungs and his explanations (with diagrams) are very clear and easy to understand.
Worth a listen.
COVID-19 treatments accelerates
Race to find COVID-19 treatments accelerates
In Section: IN DEPTH
WHO launches megatrial to test repurposed drugs and experimental drug candidates
By Kai Kupferschmidt and Jon Cohen
INFECTIOUS DISEASES
With cases of the new coronavirus disease 2019 (COVID-19) climbing steeply everywhere from Madrid to Manhattan , overwhelming one hospital after another and pushing the global death toll past 17,000, the sprint to find treatments has dramatically accelerated. Drugs that stop the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could save the lives of severely ill patients, protect health care workers and others at high risk of infection, and reduce the time patients spend in hospital beds.
The World Health Organization (WHO) last week announced a major study to compare treatment strategies in a streamlined clinical trial design that doctors around the world can join. Other trials are also underway; all told, at least 12 potential COVID-19 treatments are being tested, including drugs already in use for HIV and malaria, experimental compounds that work against an array of viruses in animal experiments, and antibody-rich plasma from people who have recovered from COVID-19. More than one strategy may prove its worth, and effective treatments may work at different stages of infection, says Thomas Gallagher, a coronavirus researcher at Loyola University Chicago’s Health Sciences Campus. “The big challenge may be at the clinical end determining when to use the drugs.”
Researchers want to avoid repeating the mistakes of the 2014–16 West African Ebola epidemic, in which willy-nilly experiments proliferated but randomized clinical trials were set up so late that many ended up not recruiting enough patients. “The lesson is you start trials now,” says Arthur Caplan, a bioethicist at New York University’s Langone Medical Center. “Make it a part of what you’re doing so that you can move rapidly to have the most efficacious interventions come to the front.”
To that end, WHO on 20 March announced the launch of SOLIDARITY, an unprecedented, coordinated push to collect robust scientific data rapidly during a pandemic. The study, which could include many thousands of patients in dozens of countries, has emphasized simplicity so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate. WHO’s website will randomize patients to local standard care or one of the four drug regimens, using only ones available at the patient’s hospital. Physicians will simply record the day the patient left the hospital or died, the duration of the hospital stay, and whether the patient required oxygen or ventilation. “That’s all,” says Ana Maria Henao Restrepo, a medical officer at WHO’s Department of Immunization Vaccines and Biologicals.
The design is not blinded: Patients will know they received a drug candidate, and that could cause a placebo effect, Henao Restrepo concedes. But it is in the interest of speed, she says. “We are doing this in record time.” The agency hopes to start to enroll patients this week.
Rather than taking years to develop and test compounds from scratch, WHO and others want to repurpose drugs that are already approved for other diseases and have acceptable safety profiles. They’re also looking at experimental drugs that have performed well in animal studies against the other two deadly coronaviruses, which cause SARS and Middle East respiratory syndrome (MERS). And they are focusing on compounds plentiful enough to treat a substantial number of patients.
COULD ONLY LOAD HALF THE ARTICLE - WRITE ME IF YOU WANT MORE
In Section: IN DEPTH
WHO launches megatrial to test repurposed drugs and experimental drug candidates
By Kai Kupferschmidt and Jon Cohen
INFECTIOUS DISEASES
With cases of the new coronavirus disease 2019 (COVID-19) climbing steeply everywhere from Madrid to Manhattan , overwhelming one hospital after another and pushing the global death toll past 17,000, the sprint to find treatments has dramatically accelerated. Drugs that stop the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could save the lives of severely ill patients, protect health care workers and others at high risk of infection, and reduce the time patients spend in hospital beds.
The World Health Organization (WHO) last week announced a major study to compare treatment strategies in a streamlined clinical trial design that doctors around the world can join. Other trials are also underway; all told, at least 12 potential COVID-19 treatments are being tested, including drugs already in use for HIV and malaria, experimental compounds that work against an array of viruses in animal experiments, and antibody-rich plasma from people who have recovered from COVID-19. More than one strategy may prove its worth, and effective treatments may work at different stages of infection, says Thomas Gallagher, a coronavirus researcher at Loyola University Chicago’s Health Sciences Campus. “The big challenge may be at the clinical end determining when to use the drugs.”
Researchers want to avoid repeating the mistakes of the 2014–16 West African Ebola epidemic, in which willy-nilly experiments proliferated but randomized clinical trials were set up so late that many ended up not recruiting enough patients. “The lesson is you start trials now,” says Arthur Caplan, a bioethicist at New York University’s Langone Medical Center. “Make it a part of what you’re doing so that you can move rapidly to have the most efficacious interventions come to the front.”
To that end, WHO on 20 March announced the launch of SOLIDARITY, an unprecedented, coordinated push to collect robust scientific data rapidly during a pandemic. The study, which could include many thousands of patients in dozens of countries, has emphasized simplicity so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate. WHO’s website will randomize patients to local standard care or one of the four drug regimens, using only ones available at the patient’s hospital. Physicians will simply record the day the patient left the hospital or died, the duration of the hospital stay, and whether the patient required oxygen or ventilation. “That’s all,” says Ana Maria Henao Restrepo, a medical officer at WHO’s Department of Immunization Vaccines and Biologicals.
The design is not blinded: Patients will know they received a drug candidate, and that could cause a placebo effect, Henao Restrepo concedes. But it is in the interest of speed, she says. “We are doing this in record time.” The agency hopes to start to enroll patients this week.
Rather than taking years to develop and test compounds from scratch, WHO and others want to repurpose drugs that are already approved for other diseases and have acceptable safety profiles. They’re also looking at experimental drugs that have performed well in animal studies against the other two deadly coronaviruses, which cause SARS and Middle East respiratory syndrome (MERS). And they are focusing on compounds plentiful enough to treat a substantial number of patients.
COULD ONLY LOAD HALF THE ARTICLE - WRITE ME IF YOU WANT MORE
Excellent update on the Covid-19 vaccine front
Today in Bloomberg;
(continued in my first comment below)
In response to:
Virus Vaccine May Be Ready for Mass Production By Autumn, Oxford Professor Says
By Jason Gale
and Stephanie Baker
April 17, 2020, 2:23 AM EDT Updated on April 17, 2020, 7:25 AM EDT
A coronavirus vaccine trial by University of Oxford researchers aims to get efficacy results by September, and manufacturing is already underway.
A team led by Sarah Gilbert, a professor of vaccinology, has recruited 500 volunteers from the ages of 18 to 55 for the early- and mid-stage randomized controlled trial. It will be extended to older adults and then to a final stage trial of 5,000 people. Gilbert said that the timing is ambitious but achievable.
“We would hope to have at least some doses that are ready to be used by September,” she said in an interview. “There won’t be enough for everywhere by then, but the more manufacturing we can do starting from now, then the more doses there will be.”
Volunteers to take part in the trial have been abundant, she said, and it’s no longer accepting new subjects.
Gilbert, whose research on vaccines began at the University of Oxford in 1994, was awarded a 2.2 million pound ($2.8 million) grant from the U.K.’s National Institute for Health Research and U.K. Research and Innovation in March to scale up her team’s efforts to move into Covid-19 vaccine research.
The group’s experimental immunization is among the first to enter clinical trials. The World Health Organization counts 70 vaccine candidates in development, with three others in human testing. They are from CanSino Biological Inc. and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc.; and Moderna Inc. along with the National Institute of Allergy and Infectious Diseases.
Gilbert’s trial divides 510 participants into five groups that will be observed for about six months with the option for a follow-up visit about a year after entering the trial. One group will receive a second intramuscular shot of the vaccine four weeks after the initial immunization.
The research aims to determine the efficacy, safety and immunogenicity of the candidate vaccine, named ChAdOx1 nCoV-19. A vaccine against meningococcal disease will be given to participants who will be randomly chosen for control purposes.
Overseas Partners?
ChAdOx1 nCoV-19 is a so-called recombinant viral vector vaccine. It’s made from a harmless virus that’s been altered to produce the surface spike protein of the pandemic-causing SARS-CoV-2 virus.
The vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response. It uses the same technology as a shot Gilbert’s team previously developed for the related MERS coronavirus. That vaccine appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version.
“We’re doing safety testing,” Gilbert said, “but we’re not concerned.”
Gilbert’s team has used the same technology for about 10 different vaccines, she said. The challenge that now arises is testing the vaccine even as virus infection rates vary.
“It’s going to be complicated trying to determine vaccine efficacy when the virus transmission in different places is going up and then going down again,” she said. “The trial has to be set up in the right place at the right time and that’s very hard to predict. That’s why we’re planning to do multiple trials in multiple countries.”
Another hurdle is money.
“We have some funding but we don’t have all of it yet,” she said. “You can’t just go and start manufacturing at large scale. You have to put a lot of things in place and that’s what we’re trying to do at the moment. It’s in the order of tens of millions of pounds.”
The WHO is creating a forum for everyone developing Covid-19 vaccines to share their plans and initial findings, according to Gilbert.
Virus Vaccine May Be Ready for Mass Production By Autumn, Oxford Professor Says
By Jason Gale
and Stephanie Baker
April 17, 2020, 2:23 AM EDT Updated on April 17, 2020, 7:25 AM EDT
A coronavirus vaccine trial by University of Oxford researchers aims to get efficacy results by September, and manufacturing is already underway.
A team led by Sarah Gilbert, a professor of vaccinology, has recruited 500 volunteers from the ages of 18 to 55 for the early- and mid-stage randomized controlled trial. It will be extended to older adults and then to a final stage trial of 5,000 people. Gilbert said that the timing is ambitious but achievable.
“We would hope to have at least some doses that are ready to be used by September,” she said in an interview. “There won’t be enough for everywhere by then, but the more manufacturing we can do starting from now, then the more doses there will be.”
Volunteers to take part in the trial have been abundant, she said, and it’s no longer accepting new subjects.
Gilbert, whose research on vaccines began at the University of Oxford in 1994, was awarded a 2.2 million pound ($2.8 million) grant from the U.K.’s National Institute for Health Research and U.K. Research and Innovation in March to scale up her team’s efforts to move into Covid-19 vaccine research.
The group’s experimental immunization is among the first to enter clinical trials. The World Health Organization counts 70 vaccine candidates in development, with three others in human testing. They are from CanSino Biological Inc. and the Beijing Institute of Biotechnology; Inovio Pharmaceuticals Inc.; and Moderna Inc. along with the National Institute of Allergy and Infectious Diseases.
Gilbert’s trial divides 510 participants into five groups that will be observed for about six months with the option for a follow-up visit about a year after entering the trial. One group will receive a second intramuscular shot of the vaccine four weeks after the initial immunization.
The research aims to determine the efficacy, safety and immunogenicity of the candidate vaccine, named ChAdOx1 nCoV-19. A vaccine against meningococcal disease will be given to participants who will be randomly chosen for control purposes.
Overseas Partners?
ChAdOx1 nCoV-19 is a so-called recombinant viral vector vaccine. It’s made from a harmless virus that’s been altered to produce the surface spike protein of the pandemic-causing SARS-CoV-2 virus.
The vaccine acts by priming the immune system to recognize and attack the coronavirus, stimulating a T-cell response. It uses the same technology as a shot Gilbert’s team previously developed for the related MERS coronavirus. That vaccine appeared to be safe in animal and early-stage human testing, giving confidence for the coronavirus version.
“We’re doing safety testing,” Gilbert said, “but we’re not concerned.”
Gilbert’s team has used the same technology for about 10 different vaccines, she said. The challenge that now arises is testing the vaccine even as virus infection rates vary.
“It’s going to be complicated trying to determine vaccine efficacy when the virus transmission in different places is going up and then going down again,” she said. “The trial has to be set up in the right place at the right time and that’s very hard to predict. That’s why we’re planning to do multiple trials in multiple countries.”
Another hurdle is money.
“We have some funding but we don’t have all of it yet,” she said. “You can’t just go and start manufacturing at large scale. You have to put a lot of things in place and that’s what we’re trying to do at the moment. It’s in the order of tens of millions of pounds.”
The WHO is creating a forum for everyone developing Covid-19 vaccines to share their plans and initial findings, according to Gilbert.
(continued in my first comment below)
A Blog is a journal you may enter about your life, your thoughts, interesting experiences, or lessons you have learned. It's your own page on Connecting Singles that you can update on a regular basis, or just whenever you have something to say. You can write about an opinion, impart words of wisdom, or talk about something interesting in your day. Creating a blog is a good way to share something of yourself with Connecting Singles members. Reading blogs is a good way to learn more about members you have met here. Please be sure to read the blog rules before posting.
Would YOU like to post a blog on Connecting Singles? Have you written blogs that you'd like to share with other members? Posting your blogs shows your skill and creativity and helps members get to know you better. Your blog will appear on the Connecting Singles Blogs page and also in a link on your profile page. Click here to post a blog »